Researchers in China have conducted a phase 1/2 trial demonstrating the safety, tolerability, and immunogenicity of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus ...
from Google Alert - health https://ift.tt/2H43aCF
via IFTTT
0 comments:
Post a Comment